000133144 001__ 133144
000133144 005__ 20240322124130.0
000133144 0247_ $$2doi$$a10.3390/healthcare12050573
000133144 0248_ $$2sideral$$a137850
000133144 037__ $$aART-2024-137850
000133144 041__ $$aeng
000133144 100__ $$aZuriaga, Estefanía
000133144 245__ $$aDescriptive Analysis of Carrier and Affected Hereditary Fructose Intolerance in Women during Pregnancy
000133144 260__ $$c2024
000133144 5060_ $$aAccess copy available to the general public$$fUnrestricted
000133144 5203_ $$a(1) Background: Hereditary fructose intolerance (HFI) is a rare autosomal recessive metabolic disorder resulting from aldolase B deficiency, requiring a fructose, sorbitol and sucrose (FSS)-free diet. Limited information exists on the relationship between pregnancy outcomes and HFI. This study aims to analyze pregnancy-related factors in a cohort of thirty Spanish women, with twenty-three being carriers and seven being HFI-affected (45 pregnancies). (2) Methods: A descriptive, cross-sectional and retrospective study utilized an anonymous questionnaire. (3) Results: Findings encompassed physical and emotional states, nutritional habits, pathology development and baby information. Notable results include improved physical and emotional states compared to the general population, with conventional analyses mostly within normal ranges. Persistent issues after pregnancy included hepatic steatosis, liver adenomas and hemangiomas. Carrier mothers’ babies exhibited higher weight than those of patient mothers, while the weights of carrier children born with HFI were similar to disease-affected children. (4) Conclusions: Pregnant women with HFI did not significantly differ in physical and emotional states, except for nausea, vomiting, and cravings. Post-pregnancy, HFI patients and carriers exhibited persistent hepatic issues. Significantly, babies born to HFI-affected mothers had lower weights. This study sheds light on pregnancy outcomes in HFI, emphasizing potential complications and the need for ongoing monitoring and care.
000133144 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B58-23R
000133144 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000133144 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000133144 700__ $$0(orcid)0000-0002-1275-2600$$aSantander, Sonia$$uUniversidad de Zaragoza
000133144 700__ $$aLomba, Laura
000133144 700__ $$aIzquierdo-García, Elsa
000133144 700__ $$0(orcid)0000-0003-4071-1467$$aLuesma, María José$$uUniversidad de Zaragoza
000133144 7102_ $$11003$$2027$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Anatom.Embriol.Humana
000133144 7102_ $$11012$$2315$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Farmacología
000133144 773__ $$g12, 5 (2024), 573 [14 pp.]$$pHealthcare (Basel)$$tHealthcare (Switzerland)$$x2227-9032
000133144 8564_ $$s835850$$uhttps://zaguan.unizar.es/record/133144/files/texto_completo.pdf$$yVersión publicada
000133144 8564_ $$s2624753$$uhttps://zaguan.unizar.es/record/133144/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000133144 909CO $$ooai:zaguan.unizar.es:133144$$particulos$$pdriver
000133144 951__ $$a2024-03-22-09:47:53
000133144 980__ $$aARTICLE